Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial

CONCLUSIONS: The addition of nicotinamide with EGFR-TKIs demonstrated potential improvements in PFS and OS, with notable survival benefits for female patients and those who had never smoked (ClinicalTrials.gov Identifier: NCT02416739).PMID:38593249 | DOI:10.1158/1078-0432.CCR-23-3059

Source: Clinical Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Hyung-Joo Oh Suk-Chul Bae In-Jae Oh Cheol-Kyu Park Kyoung-Mi Jung Da-Mi Kim Jung-Won Lee Chang Kyun Kang Il Yeong Park Young-Chul Kim Source Type: research